Outset Medical Inc. (NASDAQ: OM) saw its price target significantly reduced by TD Cowen from the previous $9.00 to $3.00, although the firm maintained a Buy rating on the stock. The adjustment follows Outset Medical's report of weaker-than-anticipated second-quarter revenue and a substantial decrease in its full-year revenue forecast.
The medical technology company reported Q2 revenue of $27.4 million, falling short of the expected $31.2 million. Additionally, Outset Medical revised its full-year revenue guidance downward to $110 million, a sharp decline from the previously projected range of $145 million to $153 million. This represents a reduction of 24-28%.
The analyst from TD Cowen highlighted that while the use of Outset Medical's Tablo system remains robust, the company is facing difficulties with the placement of new consoles. This issue is anticipated to continue affecting the company for several quarters. Despite these challenges, Outset Medical is reportedly taking steps to enhance its operational performance.
Outset Medical's second-quarter results for 2024 fell short of market expectations, leading to a downward revision of its revenue guidance to approximately $110 million, a decrease of 15.6% year-over-year.
RBC Capital responded by downgrading the company's stock from Outperform to Sector Perform and reducing the price target to $3.00. Operational execution at Outset Medical has been challenging, as evidenced by the company's recent quarterly results, despite the approval of Tablo Cart, a key product for the company.
In addition to these developments, Outset Medical reported a first quarter revenue of $28.2 million, falling short of expectations due to the TabloCart ship hold and a cyberattack. However, the company remains optimistic about meeting its annual guidance following a rebound in treatment ordering.
InvestingPro Insights
As Outset Medical Inc. (NASDAQ:OM) navigates through its current challenges, real-time data from InvestingPro provides a clearer picture of its market position. The company's market capitalization stands at a modest $69.62 million, reflecting the impact of recent events on its valuation. Notably, Outset Medical's stock has shown significant volatility, trading near its 52-week low, which aligns with the price target adjustment by TD Cowen.
InvestingPro Tips highlight that analysts have recently revised their earnings upwards for the upcoming period, indicating potential optimism in the company's ability to recover. However, it's important to note that Outset Medical is quickly burning through cash and analysts do not anticipate the company will be profitable this year. The company's valuation implies a poor free cash flow yield, a factor that investors should consider when assessing the stock's future potential. For those looking to delve deeper into Outset Medical's financial health, InvestingPro offers additional insights and tips on its platform, with a total of 11 tips currently available for Outset Medical.
With a Price / Book ratio of 1.89 as of Q1 2024, the company's assets are modestly valued in relation to its share price. Despite a revenue growth of 5.74% over the last twelve months, the quarterly figures indicate a contraction. These mixed signals underscore the importance of closely monitoring the company's performance and market trends. Outset Medical's next earnings date is set for November 5, 2024, which will be a critical event for investors to gauge the company's progress on its recovery path.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.